JP2013540749A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540749A5 JP2013540749A5 JP2013529373A JP2013529373A JP2013540749A5 JP 2013540749 A5 JP2013540749 A5 JP 2013540749A5 JP 2013529373 A JP2013529373 A JP 2013529373A JP 2013529373 A JP2013529373 A JP 2013529373A JP 2013540749 A5 JP2013540749 A5 JP 2013540749A5
- Authority
- JP
- Japan
- Prior art keywords
- skin
- pain
- diseases
- disease
- expansion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010015150 Erythema Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 208000008069 Geographic Atrophy Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 description 1
- 208000014692 Lyell syndrome Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38337010P | 2010-09-16 | 2010-09-16 | |
| US61/383,370 | 2010-09-16 | ||
| PCT/US2011/052004 WO2012037499A1 (en) | 2010-09-16 | 2011-09-16 | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540749A JP2013540749A (ja) | 2013-11-07 |
| JP2013540749A5 true JP2013540749A5 (https=) | 2016-02-04 |
| JP6073229B2 JP6073229B2 (ja) | 2017-02-01 |
Family
ID=44675870
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529360A Withdrawn JP2013541527A (ja) | 2010-09-16 | 2011-09-16 | 網膜疾患を治療するための［３−（１−（１ｈ−イミダゾール４−イル）エチル）−２−メチルフェニル］メタノールのエステル・プロドラッグ |
| JP2013529372A Active JP6045495B2 (ja) | 2010-09-16 | 2011-09-16 | 眼圧を低下させるための［３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル］メタノールのエステル・プロドラッグ |
| JP2013529373A Active JP6073229B2 (ja) | 2010-09-16 | 2011-09-16 | ［３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル］メタノールのエステル・プロドラッグ |
| JP2013529371A Withdrawn JP2013537236A (ja) | 2010-09-16 | 2011-09-16 | 皮膚疾患及び状態を治療するための［３−（１−（１ｈ−イミダゾール４−イル）エチル−２−メチルフェニル］メタノールのエステル・プロドラッグ |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529360A Withdrawn JP2013541527A (ja) | 2010-09-16 | 2011-09-16 | 網膜疾患を治療するための［３−（１−（１ｈ−イミダゾール４−イル）エチル）−２−メチルフェニル］メタノールのエステル・プロドラッグ |
| JP2013529372A Active JP6045495B2 (ja) | 2010-09-16 | 2011-09-16 | 眼圧を低下させるための［３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル］メタノールのエステル・プロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529371A Withdrawn JP2013537236A (ja) | 2010-09-16 | 2011-09-16 | 皮膚疾患及び状態を治療するための［３−（１−（１ｈ−イミダゾール４−イル）エチル−２−メチルフェニル］メタノールのエステル・プロドラッグ |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US8492557B2 (https=) |
| EP (13) | EP3050564B1 (https=) |
| JP (4) | JP2013541527A (https=) |
| KR (7) | KR101952457B1 (https=) |
| CN (5) | CN103209694A (https=) |
| AR (4) | AR083018A1 (https=) |
| AU (4) | AU2011301932C1 (https=) |
| BR (4) | BR112013006362A2 (https=) |
| CA (8) | CA2812191C (https=) |
| CL (4) | CL2013000735A1 (https=) |
| CY (3) | CY1121024T1 (https=) |
| DK (9) | DK2616068T3 (https=) |
| ES (10) | ES2607084T3 (https=) |
| HU (5) | HUE047476T2 (https=) |
| IL (4) | IL225280A0 (https=) |
| MX (4) | MX2013003004A (https=) |
| MY (4) | MY161607A (https=) |
| NZ (1) | NZ608751A (https=) |
| PL (7) | PL3348264T3 (https=) |
| PT (7) | PT2616069T (https=) |
| RU (4) | RU2013116405A (https=) |
| SG (4) | SG188571A1 (https=) |
| SI (5) | SI3348264T1 (https=) |
| TR (1) | TR201909249T4 (https=) |
| TW (4) | TW201240661A (https=) |
| UA (1) | UA112973C2 (https=) |
| WO (4) | WO2012037453A1 (https=) |
| ZA (4) | ZA201302193B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3241553B1 (en) * | 2009-02-13 | 2019-04-10 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
| US8492557B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
| CA2842866A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| EP2782569A1 (en) | 2011-11-21 | 2014-10-01 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
| USD794650S1 (en) | 2014-11-28 | 2017-08-15 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with a graphical user interface |
| CN108310442B (zh) * | 2017-01-17 | 2021-08-27 | 台北科技大学 | 眼科用组合物 |
| KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
| CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
| JP7584802B2 (ja) * | 2018-08-24 | 2024-11-18 | アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド | 高活性ｓｔｉｎｇタンパク質アゴニスト |
| WO2022221071A1 (en) * | 2021-04-16 | 2022-10-20 | Ads Therapeutics Llc | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs |
| AU2024217271A1 (en) * | 2023-02-08 | 2025-09-18 | Bausch + Lomb Ireland Limited | Alpha-2-adrenergic agonists for improving vision |
| WO2025179071A1 (en) * | 2024-02-20 | 2025-08-28 | Bausch + Lomb Ireland Limited | Sustained-release drug delivery compositions for treating ocular diseases |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69307505T2 (de) | 1992-05-13 | 1997-07-24 | Sandoz-Patent-Gmbh, 79539 Loerrach | Opthalmische zusammensetzungen enthaltend ein cyclosporin |
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| ATE234290T1 (de) | 1993-11-15 | 2003-03-15 | Schering Corp | Phenylalkyl-imidazole als h3-rezeptor- antagonisten |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| MXPA05012679A (es) * | 2003-05-27 | 2006-02-08 | Sod Conseils Rech Applic | Nuevos derivados de imidazoles, su preparacion y su uso como medicamento. |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20060209374A1 (en) * | 2003-07-14 | 2006-09-21 | Koninklijke Philips Electronics N.V. | Projection device |
| MXPA06002716A (es) * | 2003-09-12 | 2006-06-06 | Allergan Inc | Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2. |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| JP4955543B2 (ja) | 2004-05-25 | 2012-06-20 | サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド | 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法 |
| US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| NZ553341A (en) | 2004-09-24 | 2010-11-26 | Allergan Inc | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US20070082070A1 (en) * | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
| US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| JP2012517433A (ja) | 2009-02-06 | 2012-08-02 | アラーガン インコーポレイテッド | アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物 |
| EP3241553B1 (en) * | 2009-02-13 | 2019-04-10 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US8492557B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
-
2011
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active Active
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/en active
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko active Active
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en not_active Ceased
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Withdrawn
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en not_active Ceased
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active Active
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active Active
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/en active
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active Active
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/en active
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en not_active Ceased
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/en active
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en not_active Ceased
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Active
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
-
2013
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
-
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
-
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
-
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
-
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540749A5 (https=) | ||
| Ertunc et al. | Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment | |
| Nickla et al. | The multifunctional choroid | |
| Cai et al. | Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair | |
| Bronner et al. | Sexuality in patients with Parkinson's disease, Alzheimer's disease, and other dementias | |
| Araie et al. | Use of calcium channel blockers for glaucoma | |
| MX2020007318A (es) | Compuesto heterociclico. | |
| JP2009530237A5 (https=) | ||
| WO2014111815A3 (en) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction | |
| WO2013033452A3 (en) | Fgf21 for use in treating type 1 diabetes | |
| BR112015023267A2 (pt) | composto | |
| JP2018515460A5 (https=) | ||
| JP2011509297A5 (https=) | ||
| BR112014008759A2 (pt) | tratamento de doença ocular | |
| BR112013017745A2 (pt) | métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho | |
| Amersfoort et al. | T cell metabolism in metabolic disease-associated autoimmunity | |
| JOP20210039A1 (ar) | مركبات بيريدين 6،2 - ديامينو | |
| MX378486B (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
| Arbo et al. | Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation | |
| BR112015004012A2 (pt) | combinações de inibidores de sglt 2 e fármacos anti-hipertensivos | |
| WO2012177831A3 (en) | Compounds for treating peripheral neuropathies and other neurodegenerative disorders | |
| FR2961695A1 (fr) | Utilisation de composes dans le traitement ou la prevention de troubles cutanes | |
| JP2014521642A5 (https=) | ||
| MX2016012624A (es) | Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1). | |
| WO2015013777A3 (en) | Substituted benzamide derivatives as in vitro mao-b inhibitors |